1
|
Nachar W, Merlet N, Maafi F, Mihalache-Avram T, Mecteau M, Gélinas D, Shi Y, Brodeur M, Alem S, Blondeau L, Cossette M, Guertin MC, Rhainds D, Busseuil D, Rhéaume E, Tardif JC. ApoA-I mimetic does not improve left ventricular diastolic dysfunction in rabbits without aortic valve stenosis. Int J Cardiol 2021; 331:199-205. [PMID: 33421451 DOI: 10.1016/j.ijcard.2020.12.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 12/23/2020] [Accepted: 12/30/2020] [Indexed: 11/24/2022]
Abstract
BACKGROUND We previously demonstrated that high-density lipoprotein (HDL) infusions may improve left ventricular diastolic dysfunction (LVDD) in an aortic valve stenosis (AVS) model. Whether the benefit was direct or mediated by the observed reduction in AVS severity is not clear. Here, we aimed to test the direct effect of an ApoA-I mimetic on LVDD in the absence of AVS. METHODS Rabbits were exposed to three different protocols to develop LVDD. First, rabbits were exposed to 0.5% cholesterol-rich diet for an average of 17 weeks. Second, rabbits were subjected to surgical ascending aortic constriction (AAC), to mimic the effect of fixed reduced aortic valve area, and studied after 10 weeks. The third model combined both cholesterol-enriched diet (for 12 weeks) and surgical AAC. The control group consisted of age-matched rabbits under normal diet. After development of LVDD, rabbits were randomized to receive infusions of saline or apoA-I mimetic (25 mg/kg) 3 times per week for 4 weeks. Detailed cardiac structure and function measurements were assessed at baseline and weekly during treatment period. Histological and molecular analyses were performed on LV samples. RESULTS In the three models, echocardiographic results showed development of LVDD over time, with preserved LV systolic and aortic valve functions versus controls. ApoA-I mimetic infusions did not significantly improve echocardiographic parameters nor molecular markers of cardiac inflammation, oxidative stress and fibrosis. CONCLUSION ApoA-I mimetic therapy did not directly improve LVDD. These results indicate that previously observed changes of LVDD were caused by AVS improvement induced by this treatment.
Collapse
Affiliation(s)
- Walid Nachar
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada; Department of medicine, Université de Montréal, 2900 Edouard-Montpetit boulevard, Montreal H3T 1J4, Canada
| | - Nolwenn Merlet
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Foued Maafi
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada; Department of medicine, Université de Montréal, 2900 Edouard-Montpetit boulevard, Montreal H3T 1J4, Canada
| | | | - Mélanie Mecteau
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Danielle Gélinas
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Yanfen Shi
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Mathieu Brodeur
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Sonia Alem
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Lucie Blondeau
- Montreal Health Innovations Coordinating Centre (MHICC), 4100 Molson Street, Montreal H1Y 3N1, Canada
| | - Mariève Cossette
- Montreal Health Innovations Coordinating Centre (MHICC), 4100 Molson Street, Montreal H1Y 3N1, Canada
| | - Marie-Claude Guertin
- Montreal Health Innovations Coordinating Centre (MHICC), 4100 Molson Street, Montreal H1Y 3N1, Canada
| | - David Rhainds
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - David Busseuil
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada
| | - Eric Rhéaume
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada; Department of medicine, Université de Montréal, 2900 Edouard-Montpetit boulevard, Montreal H3T 1J4, Canada
| | - Jean-Claude Tardif
- Montreal Heart Institute, 5000 Belanger Street, Montreal H1T 1C8, Canada; Department of medicine, Université de Montréal, 2900 Edouard-Montpetit boulevard, Montreal H3T 1J4, Canada.
| |
Collapse
|
2
|
Merlet N, Busseuil D, Mihalache-Avram T, Mecteau M, Shi Y, Nachar W, Brand G, Brodeur MR, Charpentier D, Rhainds D, Sy G, Schwendeman A, Lalwani N, Dasseux JL, Rhéaume E, Tardif JC. HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits. Int J Cardiol 2016; 215:364-71. [PMID: 27128563 DOI: 10.1016/j.ijcard.2016.04.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Revised: 03/29/2016] [Accepted: 04/03/2016] [Indexed: 01/09/2023]
Abstract
OBJECTIVES High-density lipoprotein (HDL) infusions induce rapid improvement of experimental atherosclerosis in rabbits but their effect on ventricular function remains unknown. We aimed to evaluate the effects of the HDL mimetic peptide CER-522 on left ventricular diastolic dysfunction (LVDD). METHODS Rabbits were fed with a cholesterol- and vitamin D2-enriched diet until mild aortic valve stenosis and hypercholesterolemia-induced LV hypertrophy and LVDD developed. Animals then received saline or 10 or 30mg/kg CER-522 infusions 6 times over 2weeks. We performed serial echocardiograms and LV histology to evaluate the effects of CER-522 therapy on LVDD. RESULTS LVDD was reduced by CER-522 as shown by multiple parameters including early filling mitral deceleration time, deceleration rate, Em/Am ratio, E/Em ratio, pulmonary venous velocities, and LVDD score. These findings were associated with reduced macrophages (RAM-11 positive cells) in the pericoronary area and LV, and decreased levels of apoptotic cardiomyocytes in CER-522-treated rabbits. CER-522 treatment also resulted in decreased atheromatous plaques and internal elastic lamina area in coronary arteries. CONCLUSIONS CER-522 improves LVDD in rabbits, with reductions of LV macrophage accumulation, cardiomyocyte apoptosis, coronary atherosclerosis and remodelling.
Collapse
|